Association of Perioperative Vasodilator Therapy and Mortality in Nonocclusive Mesenteric Ischemia
Journal of Surgical Research · 2025
DOI: 10.1016/j.jss.2025.08.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Research, 2025. Verfasst von Takuya Takami und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan; Department of Surgery, Graduate Sc…. Hauptthemen laut MEDLINE: Vasodilator Agents, Mesenteric Ischemia, Perioperative Care, Postoperative Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Nonocclusive mesenteric ischemia (NOMI) is a life-threatening condition characterized by mesenteric hypoperfusion without arterial occlusion and is associated with a high mortality rate. Although vasodilator therapy is recommended in clinical guidelines, its effectiveness in surgical cases of NOMI remains unclear. In this study, we aimed to evaluate the effectiveness of perioperative vasodilator therapy in patients undergoing surgery for NOMI, using a nationwide real-world database in Japan. METHODS: A retrospective cohort study was conducted using data from 2014 to 2024. Patients who underwent surgery for NOMI were included and categorized into a vasodilator group (those who received prostaglandin E1 or papaverine hydrochloride within 1 d before or after surgery) and a nonvasodilator group. Inverse probability of treatment weighting with stabilized weights was applied to adjust for baseline differences. The primary outcome was 30-d mortality. Secondary outcomes included in-hospital mortality, reoperation proportion, and complication proportion. RESULTS: A total of 702 patients were analyzed (86 in the vasodilator group and 616 in the nonvasodilator group). After inverse probability of treatment weighting, baseline characteristics were well balanced. The vasodilator group showed significantly lower 30-d mortality (weighted hazard ratio, 0.44; 95% confidence interval (CI), 0.22-0.88) and in-hospital mortality (weighted risk ratio, 0.62; 95% confidence interval, 0.40-0.96). Reoperation and complication proportions did not differ significantly between the groups. CONCLUSIONS: Perioperative vasodilator therapy was associated with reduced mortality in patients undergoing surgery for NOMI. These findings suggest that vasodilator therapy may serve as a beneficial adjunct in the surgical management of NOMI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan; Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan; Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health, Kyoto Univ…
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan. Electronic address: kawakami.koji.4e@kyoto-u.ac.jp.
Zitieren
APA
Takami, T., Mizuno, K., Obama, K., & Kawakami, K. (2025). Association of Perioperative Vasodilator Therapy and Mortality in Nonocclusive Mesenteric Ischemia. Journal of Surgical Research. https://doi.org/10.1016/j.jss.2025.08.017
Vancouver
Takami T, Mizuno K, Obama K, Kawakami K. Association of Perioperative Vasodilator Therapy and Mortality in Nonocclusive Mesenteric Ischemia. Journal of Surgical Research. 2025. doi:10.1016/j.jss.2025.08.017
BibTeX
@article{Takami2025,
author = {Takami, Takuya and Mizuno, Kayoko and Obama, Kazutaka and Kawakami, Koji},
title = {Association of Perioperative Vasodilator Therapy and Mortality in Nonocclusive Mesenteric Ischemia},
journal = {Journal of Surgical Research},
year = {2025},
doi = {10.1016/j.jss.2025.08.017}
}
EUVIMED